vTv Therapeutics

$2.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-7.38%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VTVT and other stocks, options, and ETFs commission-free!

About VTVT

vTv Therapeutics Inc. Class A Common Stock, also called vTv Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC. The listed name for VTVT is vTv Therapeutics Inc. Class A Common Stock.

CEO
Stephen L. Holcombe
Employees
26
Headquarters
High Point, North Carolina
Founded
2015
Market Cap
206.30M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.39M
High Today
$2.48
Low Today
$2.15
Open Price
$2.39
Volume
1.74M
52 Week High
$4.75
52 Week Low
$1.44

VTVT Earnings

-$0.11
-$0.07
-$0.02
$0.02
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
$0.02 per share

You May Also Like

APSG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure